Summary: A monoclonal antibody (NDOG2) against placental alkaline phosphatase (PLAP) in ovarian cancer has been used in three ways by the Bristol University Department of Obstetrics & Gynaecology. First, in an indirect immunoperoxidase technique, NDOG2 demonstrated positive standing in 64% of 56 ovarian carcinomas as well as in 25% of 44 benign tumours. The majority of these positive tumours were serous cystadenocarcinomas or serous cystadenomas and there was considerable variation in the expression of this antigen from tumour to tumour. NDOG2 was also used as the basis of two serum assays and, when labelled with 123-iodine (1231), in radioimmunoscintigraphy (RIS) to monitor patients' response to therapy. The first serum assay measures the enzymic activity of PLAP and the second recognizes the antigenicity of the molecules. Assay 2 proved more useful in that it predicted the course of the disease in 45% of patients followed up, whereas Assay 1 was only of use in 25% of cases. RIS proved to be a useful imaging technique and was at least as sensitive as conventional imaging techniques. The common causes of false-positive and false-negative results are described.
Introduction
Ovarian cancer is the most commonly occurring gynaecological malignancy in the United Kingdom (OPCS 1983) and, because of its propensity for intra-abdominal metastasis, presents particular problems in assessing a patient's response to therapy. In addition, it is a cancer that tends to present as advanced disease and there is no widely available simple screening test to detect this tumour at an early stage.
There are two potential methods of screening a patient for this disease and monitoring response to therapy. The first involves the use of a biochemical serum tumour marker, but although in gynaecological practice human chorionic gonadotrophin (Newlands et al. 1982) and alphafetoprotein (Sell et al. 1976 ) have proved useful in the management of certain ovarian germ cell tumours, no similar markers exist for epithelial ovarian cancer. Indeed, over 40 potential tumour markers have been described (Umbach 1984) but none has proved outstanding in this disease.
PLAP was first described in association with ovarian cancer by Stolbach et al. (1969) , and subsequent confirmation by other workers suggests an overall expression of PLAP by 22-39% of such tumours (Nathanson & Fishman 1971 , Van Nagell et al. 1981 , McLaughlin et al. 1983 ). There has been much debate about the value of PLAP as a tumour marker in this disease: Haije et al. (1979) found it to be of value in 86% of patients studied, but others (Burrows 1980 , Doellgast & Homesley 1984 found it of no use at all.
The NDOG2 monoclonal antibody recognizes the three common allelic forms of PLAP (Sunderland et al. 1984) and apositive reactive staining has been demonstrated in normal fallopian tube, endometrial and endocervical epithelium as well as lung and thymus (Sunderland et al. 1984 , Davies et al. 1985b . Its distribution in normal and ovarian malignancy tissue is similar to that of another tumour-associated antigen, CA 125 (Davies et al. 1985c) .
The second method of assessing a patient's response to therapy involves the use of an imaging technique. X-ray computed tomography (CT) and ultrasound scanning (USS) have limited sensitivity when applied to small, solid, intra-abdominal tumour deposits, particularly in the case of CT, after primary surgery (Piver 1983) . In addition, neither of these techniques can distinguish between viable and dead tumour. Radiolabelled antibodies to locate tumour deposits are potentially useful in the management of this disease and a number of monoclonal antibodies have been used in this way, e.g. HMFG2 (Epenetos et al. 1982) and H317 (P M Johnson, personal communication). NDOG2 has been similarly used to demonstrate both primary and recurrent ovarian tumour deposits (Davies et al. 1985a , Jackson et al. 1985 and this paper describes the use of this antibody both in RIS and as the basis of two serum assays.
Methods Immunohistology
The indirect immunoperoxidase technique used on frozen sections of normal and malignancy tissue has been described previously (Sunderland et al. 1984 , Davies et al. 1985b ). Assay 2: Microtitre well plates (Flow) were coated with 50 ml of 10 ,ug/ml purified NDOG2 in a carbonate coating buffer pH 9.6, by overnight incubation at 4°C, and active sites on each well were then blocked by incubation with 100 1il of 10% fetal calf serum for 2 hours at room temperature. A calibration line of 50 gl of 18 serial dilutions of purified PLAP (Sigma) from 10 mg/ml to zero or 50 p1 of test serum were incubated, in duplicate, at 4°C for one hour. The plates were washed 3 times in PBS 0.05% Tween 20 and each well incubated with 50 jl of rabbit antihuman PLAP (Dako) in a 1:250 dilution for 30 min at 4°C. A further washing step was performed before incubation for 30 min at 4°C with 50 gl of a 1 in 1000 dilution of a peroxidase conjugated goat anti-rabbit immunoglobulin (Miles). The plates were again washed and the colour developed by incubation with 100 I of the substrate, orthophenyl diamine. The reaction was stopped with 50 g.l of 2.5 mol H2SO4 and the plates read in a Tietertock multiskan spectrophotometer at 492 nM.
Radioimmunoscintigraphy
Purified NDOG2 was labelled with 1231I (Harwell) using the chloramine T method (Davies et al. 1985a ). This method ensured retention of 90% of the specific activity of the labelled antibody when compared in Assay 1 with the unlabelled form. Sequential images of pelvis, abdomen, chest, head and neck were obtained at Omin (early image), 4 h (intermediate image) and 20 h (late image) after intravenous injection of 250 1ig of the labelled antibody ('23INDOG2). This preparation had an activity of 1-2 mCi.
Patients Forty-four patients were followed up using both serum assays for bet-ween 4 and 26 months (mean 9.8 months), during which time 27 patients (61%) had either died of their disease or developed a large tumour recurrence. Serum samples were collected when possible preoperatively, then at monthly intervals during therapy and thereafter at 3-monthly intervals.
RIS was performed on 20 patients with actual or suspected ovarian cancer. All patients received a thyroid-blocking agent (potassium iodide or potassium perchlorate) prior to imaging and, with the exception of one patient who had a previously unknown allergy to potassium iodide, no untoward reactions were noted. (Table 1) . Of 44 benign tumours, 11 showed positive staining with NDOG2 and of these 8 were serous cystadenomas. However, in the case of ovarian cancer, 65% of the 56 tumours examined showed positive reactive staining with NDOG2 (e.g. Figure 1 ) and again these were predominantly of the serous histological type (Table 1) . Assay 2 measures PLAP in ,ug/ml and does not rely on PLAP activity to give a result. A wide range of values was found in both the normal non-smoking, healthy population and in cigarette smokers, but again these latter tended to have higher levels overall.
Comparison ofpreoperative levels and tumour immunohistology: There was a close relationship between the degree of reactive staining of the tumour and the preoperative serum levels from both assays. Those tumours with the greater degree of staining tended to have higher serum levels ( Table 2) .
Value in predicting the course ofthe disease: PLAP activity, as measured by Assay 1, proved to be a useful marker in 11 cases (e.g. Figure 2 ) and in a further 4 cases it initially predicted the course of the disease but then fell, inappropriately, prior to the patient's death (e.g. Figure 3 ). There were two false-negative results using this assay, both due to cigarette smoking. A change in levels of PLAP, as measured by Assay 2, accurately predicted the course of the disease in these 11 patients and in a further 9 cases (e.g. Figures 2 and 3) . In 7 more patients an initial accurate reflection of the course of the disease was followed by an inappropriate fall in levels prior to the patient's death. There were 4 false-positive results, 2 of which -as in Assay l-were due to cigarette smoking, but 2 patients showed an unexplained, transient rise in serum levels. All 4 patients remain well and are apparently still in remission.
Radioimmunoscintigraphy: This has proved a relatively sensitive method of visualizing intra-abdominal and pelvic tumour deposits (Davies et al. 1985c ) and appears to be at least as accurate as CT or USS in this respect (Tables 3 & 4) . Two distinct abnormalities due to a tumour deposits have been recognized. The first of these, a focal abnormality (Figure 4) , corresponds to a discrete tumour deposit, whereas a diffuse abnormality ( Figure 5 ) corresponds to widespread intra-abdominal and pelvic disease. However, this imaging technique is not without causes of false-positive results, the commonest of which is due to incomplete blocking of uptake of 123I by the thyroid gland or gut mucosa; in this respect potassium iodide was found to be superior to potassium perchlorate as a blocking agent. Hydronephrosis or chronic retention of urine by the bladder are also causes of false-positive results, but 123I in a full bladder may also mask a genuine pelvic tumour. Subtraction artifacts are generated by inaccurate repositioning of the patient before the intermediate or late images are obtained, leading to false-positive results when the early (blood pool) image is subtracted from these later images. In the majority of cases imaged in this study, subtraction was not necessary to visualize tumour deposits. RIS using '23INDOG2 has a false-negative rate. Obviously if a patient whose tumour does not express PLAP is imaged, then that tumour will not be visualized (patient 11, Table 5 ).
However, if a PLAP-producing tumour metastasis is near or in an area of high background activity, e.g. liver or the para-aortic nodes (patients 3 and 5, Table 5 ) then a negative image can be obtained. Scanty small tumour deposits may also be missed (e.g. patients 3, 5, 9 and 18, Table 5 ).
Discussion
Positive reactive staining with NDOG2 has been demonstrated on a substantial percentage of the ovarian carcinomas studied, predominantly serous cystadenocarcinomas. However, PLAP is not a tumour-specific antigen, as positive reactive staining has been demonstrated in a few normal tissues; but 3 of these -fallopian tube, uterus and cervix -are usually removed at the time of primary surgery. The tumour specificity of NDOG2 therefore compares favourably with other monoclonal antibodies currently used to monitor patients with ovarian cancer, e.g. HMFG2 (Epenetos et al. 1982) and OC125 (Bast et al. 1981 , Davies et al. 1985c .
RIS using 1231INDOG2 is a relatively accurate imaging technique and a useful method of monitoring a patient's response to therapy. However, in common with other imaging techniques (CT and USS), it has its share of false-positive and false-negative results. RIS is a relatively time-consuming procedure and must, by definition, carry a potential radiation hazard, albeit small, and so is not a realistic screening method for use in the general population.
The serum assays, based on NDOG2, both gave useful information in a percentage of the patients followed up, but again both have drawbacks. The first assay, based on PLAP activity, was of use in only 25% of patients followed up whereas the second assay was of value in 45% of cases. The problem in both assays concerns false-positive results: in Assay I this is solely due to cigarette smoking, but in Assay 2 there are other factors that cause high levels in the normal population. It is likely that Assay 2 is measuring something in addition to enzymically active PLAP. Figure 3 shows the response to therapy of a patient who ultimately died from her tumour. Initially both assays reflected the course of her disease, but in the latter stages of her illness Assay 1 returned to near normal levels, whereas Assay 2, after an initial fall, rose -reflecting the patient's rapidly growing tumour. This can perhaps be explained by Assay 2 recognizing both active PLAP and another tumour-associated antigen, which could be either an enzymically inactive form of the molecule or a hybrid molecule. The Wamock variant of alkaline phosphatase (Warnock & Reisman 1969 ) is such a hybrid existing as a dimer, with one subunit from PLAP and the other subunit from intestinal alkaline phosphatase (Higashimo et al. 1972) . Assay 2 could recognize such a variant, as NDOG2 recognizes PLAP alone and the second layer rabbit anti-human PLAP antibody cross-reacts with intestinal alkaline phosphatase (Dako Data Sheet 1984) .
These assays have proved useful in the management of patients with ovarian cancer, but neither offers an ideal screening test for the general population. Assay 2 has no definite upper limit of normal and both assays are affected by cigarette smoking. Work is presently in progress to try and develop a panel of monoclonal antibodies to recognize other carcinoplacental antigens in order to be able accurately to follow up a greater percentage of patients with ovarian cancer. Hopefully these antibodies will, in the future, form the basis of a screening test for the general population.
